|
|
||||||||
a Heart, Lung, and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
b Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
c University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
d University of Pittsburgh Cancer Institute Biostatistics Facility, Pittsburgh, Pennsylvania
Accepted for publication January 28, 2008.
* Address correspondence to Dr Luketich, Heart, Lung and Esophageal Surgery Institute, Department of Cardiothoracic Surgery, University of Pittsburgh, Suite C-800, 200 Lothrop St, Pittsburgh PA 15213 (Email: luketichjd{at}upmc.edu).
Presented at the Forty-third Annual Meeting of The Society of Thoracic Surgeons, San Diego, CA, Jan 29–31, 2007.
Background: Effective systemic therapy is considered essential to improve the outcome for patients with surgically resectable locally advanced esophageal carcinoma. We report the long-term results of our phase II study of neoadjuvant chemotherapy, followed by esophagectomy and adjuvant chemotherapy for potentially resectable esophageal carcinoma.
Methods: Patients were staged with computed tomography scan (n = 70), endoscopic ultrasonography (n = 63), and laparoscopy with or without thoracoscopy (n = 70). The pretreatment stages were T2N0 (n = 1), T2N1 (n = 15), T3N0 (n = 13), and T3N1 (n = 41). Chemotherapy consisted of 2 or 3 cycles of cisplatin, 5-fluorouracil, and paclitaxel followed by esophagectomy and adjuvant chemotherapy. Patients were monitored for recurrence and survival.
Results: A total of 70 patients were enrolled (66 adenocarcinoma, 4 squamous cell carcinoma; 64 men and 6 women; median age, 60 years). Esophagectomy was performed in 63 patients. Operative mortality was 0%. The median overall survival of the entire group was 27.4 months. Seventeen patients were alive at a median follow-up of 62.8 months (range, 39.1 to 142). Fourteen patients were alive without recurrence at a median follow-up of 79 months (range, 39 to 138). Nodal status was an important predictor of overall survival. Patients who were downstaged experienced a significantly improved median survival of 63.4 months versus 21.5 months and overall survival (p = 0.005).
Conclusions: This prospective study for esophageal carcinoma demonstrates encouraging long-term results. In particular, downstaging of the tumor with preoperative chemotherapy is predictive of better long-term outcome. Our results support the role for perioperative chemotherapy for locally advanced resectable esophageal cancer.
This article has been cited by other articles:
![]() |
A. Feber, L. Xi, A. Pennathur, W. E. Gooding, S. Bandla, M. Wu, J. D. Luketich, T. E. Godfrey, and V. R. Litle MicroRNA Prognostic Signature for Nodal Metastases and Survival in Esophageal Adenocarcinoma Ann. Thorac. Surg., May 1, 2011; 91(5): 1523 - 1530. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Solomon, D. Mezentsev, I. Reis, M. Lima, J. Rios, E. Avisar, D. Franceschi, A. Livingstone, L. Podolsky, and B. Ardalan A Phase II Study of Neoadjuvant and Adjuvant Chemotherapy with 5-Fluorodeoxyuridine, Leucovorin, Oxaliplatin and Docetaxel in the Treatment of Previously Untreated Advanced Esophageal Adenocarcinoma Jpn. J. Clin. Oncol., April 1, 2011; 41(4): 469 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Tomaszek, S. D. Cassivi, M. S. Allen, K. R. Shen, F. C. Nichols III, C. Deschamps, and D. A. Wigle An alternative postoperative pathway reduces length of hospitalisation following oesophagectomy, Eur J Cardiothorac Surg, April 1, 2010; 37(4): 807 - 813. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |